The notes were issued pursuant to an indenture, dated May 7, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.
CanSinoBIO is responsible for the chemistry, manufacturing, and controls development and manufacture of clinical supplies of such products and is responsible for the costs associated with such activities.
Ocugen, Inc. Customers
No clients on recordNo downstream customers found in our database for Ocugen, Inc..
Ocugen, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OCGN-DEBT
Debt stack $33.3M
90%
Market cache reports total debt of $33.3M.
OCGN-DEBT-11483
Warrants outstanding: 156138
90%
xbrl warrant detail from xbrl 2026-03-31.
OCGN-DEBT-11484
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
Ocugen, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Ocugen, Inc..
Ocugen, Inc. Ownership
Holder
Name
Confidence
Evidence
OCGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 140 tracked holders.
Ocugen, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
